|
IMMUNODEFICIENCY 40
|
0.700 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
The Rac Activator DOCK2 Mediates Plasma Cell Differentiation and IgG Antibody Production.
|
29503648 |
2018 |
|
IMMUNODEFICIENCY 40
|
0.700 |
GermlineCausalMutation
|
disease |
ORPHANET |
Inherited DOCK2 Deficiency in Patients with Early-Onset Invasive Infections.
|
26083206 |
2015 |
|
IMMUNODEFICIENCY 40
|
0.700 |
GeneticVariation
|
disease |
UNIPROT |
Inherited DOCK2 Deficiency in Patients with Early-Onset Invasive Infections.
|
26083206 |
2015 |
|
IMMUNODEFICIENCY 40
|
0.700 |
GeneticVariation
|
disease |
CLINVAR |
Inherited DOCK2 Deficiency in Patients with Early-Onset Invasive Infections.
|
26083206 |
2015 |
|
IMMUNODEFICIENCY 40
|
0.700 |
Biomarker
|
disease |
CTD_human |
|
|
|
|
IMMUNODEFICIENCY 40
|
0.700 |
CausalMutation
|
disease |
CLINVAR |
|
|
|
|
Prostate cancer, familial
|
0.300 |
Biomarker
|
disease |
CTD_human |
Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci.
|
29892016 |
2018 |
|
PROSTATE CANCER, HEREDITARY, 1
|
0.300 |
Biomarker
|
disease |
CTD_human |
Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci.
|
29892016 |
2018 |
|
Adenocarcinoma Of Esophagus
|
0.300 |
Biomarker
|
disease |
CTD_human |
Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity.
|
23525077 |
2013 |
|
Leukemia, Myelocytic, Acute
|
0.130 |
Biomarker
|
disease |
BEFREE |
These findings suggest that FLT3-ITD and Rac1 activity cooperatively modulate DNA repair activity, the addition of DNA damage response inhibitors to conventional chemotherapy may be useful in the treatment of FLT3-ITD AML, and inhibition of the Rac signaling pathways via DOCK2 may provide a novel and promising therapeutic target for FLT3-ITD AML.
|
30975911 |
2019 |
|
Leukemia, Myelocytic, Acute
|
0.130 |
Biomarker
|
disease |
BEFREE |
We first analyzed data of 85 AML patients who were treated with chemotherapy and had available DOCK1 to DOCK11 expression information and found that DOCK1 and DOCK2 had prognostic significance in AML.
|
31762818 |
2019 |
|
Leukemia, Myelocytic, Acute
|
0.130 |
GeneticVariation
|
disease |
GWASCAT |
Genome-wide haplotype association study identify the FGFR2 gene as a risk gene for acute myeloid leukemia.
|
27903959 |
2017 |
|
Leukemia, Myelocytic, Acute
|
0.130 |
Biomarker
|
disease |
BEFREE |
These findings suggest that DOCK2 is a potential therapeutic target for novel AML treatments, as this protein regulates the survival of leukemia cells with elevated FLT3 activity and sensitizes FLT3/ITD leukemic cells to conventional antileukemic agents.
|
27748370 |
2017 |
|
Lymphopenia
|
0.110 |
Biomarker
|
disease |
BEFREE |
Although absence of DOCK2 leads to lymphopenia, little is known about the signaling mechanisms and physiologic functions of DOCK2 in B cells.
|
31405607 |
2019 |
|
Lymphopenia
|
0.110 |
Biomarker
|
disease |
HPO |
|
|
|
|
Intelligence
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Genome-wide association meta-analysis in 269,867 individuals identifies new genetic and functional links to intelligence.
|
29942086 |
2018 |
|
Adolescent idiopathic scoliosis
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
The coexistence of copy number variations (CNVs) and single nucleotide polymorphisms (SNPs) at a locus can result in distorted calculations of the significance in associating SNPs to disease.
|
30019117 |
2018 |
|
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci.
|
29892016 |
2018 |
|
SCOLIOSIS, ISOLATED, SUSCEPTIBILITY TO, 3
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
The coexistence of copy number variations (CNVs) and single nucleotide polymorphisms (SNPs) at a locus can result in distorted calculations of the significance in associating SNPs to disease.
|
30019117 |
2018 |
|
Leptin measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
A genome-wide association study identifies protein quantitative trait loci (pQTLs).
|
18464913 |
2008 |
|
Immunologic Deficiency Syndromes
|
0.100 |
Biomarker
|
group |
HPO |
|
|
|
|
Malignant Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
This review summarizes the latest research progresses on the role of Dock2 for the development of various inflammatory diseases and cancers, and discusses the potential application of Dock2 modulators for patient treatment.
|
29509960 |
2018 |
|
Colorectal Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Our findings demonstrated that overexpressed DOCK2 might involve in recruiting CD8<sup>+</sup> T lymphocytes and serve as a novel prognostic indicator and indicated a potential therapeutic strategy by restoring DOCK2 for CRC.
|
30076747 |
2018 |
|
Tumor Cell Invasion
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
Moreover, DOCK2 expression was positively associated with invasion depth (P < .001) and tumor size (P = .016).
|
30076747 |
2018 |
|
Tumor Cell Invasion
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
A locus on Chr4 associated with both ACLR and TPA resides within DOCK2, a gene that has been shown to promote immune cell migration and invasion in synovitis, an important predictor of ACLR.
|
29940858 |
2018 |